Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012 for this...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards mRNA therapeutics 2.0.

Nature reviews. Drug discovery·2026
Same author

Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.

Blood advances·2026
Same author

Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.

The New England journal of medicine·2025
Same author

Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy.

Circulation·2025
Same author

Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies.

Lancet (London, England)·2025
Same author

Multifaceted analysis of noncoding and coding de novo variants implicates NOTCH signaling pathway in tetralogy of Fallot in Chinese population.

HGG advances·2025

Related Experiment Video

Updated: May 20, 2026

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

In vivo reprogramming for heart disease.

Huansheng Xu1, B Alexander Yi, Kenneth R Chien

  • 11] Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.

Cell Research
|July 4, 2012
PubMed
Summary

Scientists achieved direct lineage reprogramming in the heart, converting one cell type to another without pluripotency. This offers a novel regenerative approach for cardiac therapeutics.

Area of Science:

  • Cardiovascular Biology
  • Regenerative Medicine
  • Cellular Reprogramming

Background:

  • Lineage reprogramming typically converts somatic cells without a pluripotent stage.
  • Cardiac cell-based therapies face challenges in regeneration and repair.

Purpose of the Study:

  • To investigate the feasibility of in situ cardiac lineage reprogramming.
  • To explore a novel regenerative strategy for cardiac conditions.

Main Methods:

  • Direct conversion of cardiac cell types within the heart.
  • In vivo studies demonstrating cellular transdifferentiation.

Main Results:

  • Successful demonstration of lineage reprogramming directly within the heart.
  • Evidence of cell type conversion without intermediate pluripotent states.

More Related Videos

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
05:04

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter

Published on: February 22, 2022

Related Experiment Videos

Last Updated: May 20, 2026

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
05:04

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter

Published on: February 22, 2022

Conclusions:

  • In situ cardiac lineage reprogramming is achievable.
  • This approach presents a promising avenue for developing new cardiac regenerative therapies.